C12N2770/24034

PRODUCTION OF VIRUSES IN AVIAN EGGS

The present invention relates to modified avian eggs which can be used to produce increased levels of virus. The present invention also relates to methods of producing viruses in avian eggs of the invention, as well as the use of the viruses obtained to prepare vaccine compositions.

COMPOSITIONS AND METHODS FOR STABILIZING FLAVIVIRUSES WITH IMPROVED FORMULATIONS

Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.

High potency immunogenic zika virus compositions
10273269 · 2019-04-30 · ·

Provided herein, in some embodiments, are Zika Virus immunogenic compositions that include a cationic lipid nanoparticle (LNP) encapsulating messenger ribonucleic acid (mRNA) having an open reading frame encoding Zika Virus antigens, a pan HLA DR-binding epitope (PADRE), and a 5 terminal cap modified to increase mRNA translation efficiency.

Chikagunya virus RNA vaccines

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

ZIKA VIRUS RNA VACCINES

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

CHIKUNGUNYA VIRUS RNA VACCINES

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

PRODUCTION OF VIRUSES IN AVIAN EGGS

The present invention relates to modified avian eggs which can be used to produce increased levels of virus. The present invention also relates to methods of producing viruses in avian eggs of the invention, as well as the use of the viruses obtained to prepare vaccine compositions.

Zika virus RNA vaccines

The disclosure relates to Zika virus infection and the treatment thereof. The invention includes ribonucleic acid compositions, as well as methods of using the compositions for treating and preventing Zika virus infection.

HIGH POTENCY IMMUNOGENIC COMPOSITIONS
20180312549 · 2018-11-01 · ·

Provided herein, in some embodiments, are immunogenic compositions that include a cationic lipid nanoparticle (LNP) encapsulating messenger ribonucleic acid (mRNA) having an open reading frame encoding a viral, bacterial or parasitic antigen, a pan HLA DR-binding epitope (PADRE), and a 5 terminal cap modified to increase mRNA translation efficiency.

VACCINE COMPOSITION FOR CLASSICAL SWINE FEVER FROM PLANT AND MANUFACTURING METHOD THEREOF

A recombinant vector for transforming a plant, a plant transformed with the recombinant vector, a plant-made classical swine fever virus antigen pmE2 protein expressed in the plant and uses thereof is provided. By using a recombinant vector having a polynucleotide encoding a GP55 protein of CSFV according to the present invention; and a polynucleotide encoding a cellulose-binding domain protein; and a plant transformed with the recombinant vector, a plant-made classical swine fever virus antigen pmE2 protein may be produced with high efficiency, and has higher safety and stability than those achieved by other production methods. Also, since the plant-derived classical swine fever virus antigen protein pmE2 has a cellulose-binding domain (CBD) protein, it may be usefully used as an effective marker to determine a virus exposure pathway and an antibody producing pathway.